Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast CancerAditya Bardia, Linda T. Vahdat, Vandana G. Abramson et al.|Journal of Clinical Oncology|2017Cited by 407
Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trialAditya Bardia, Allyson J. Ocean, Wells A. Messersmith et al.|Annals of Oncology|2021Cited by 371
First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid TumorsAlexander Starodub, David M. Goldenberg, Allyson J. Ocean et al.|Clinical Cancer Research|2015Cited by 344
Sacituzumab govitecan (IMMU‐132), an anti‐Trop‐2‐SN‐38 antibody‐drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokineticsAllyson J. Ocean, David M. Goldenberg, Alexander Starodub et al.|Cancer|2017Cited by 235
Abstract A081: Resistance Mechanisms to Monotherapy RAS(ON) Multi-Selective Inhibitor Daraxonrasib (RMC-6236) in RAS Mutant PDAC Inform Therapeutic Combination StrategiesIda Aronchik, Mallika Singh, Sumit Kar et al.|Molecular Cancer Therapeutics|2025Cited by 1